Prediabetes, Malignant Ventricular Hypertrophy and Stroke: The SPRINT Trial
Authors' conclusion
Among hypertensive adults, the coexistence of prediabetes and malignant LVH substantially increased stroke risk.
Study context
- Population
- Hypertensive adults without DM or prior stroke from SPRINT; mean age 68 ± 9.4 years, 36.8% women, 39.8% with prediabetes
- Participants
- 8,367 adults
- Comparison
- Categories of glycemic status and malignant left ventricular hypertrophy (LVH) vs normoglycemia without malignant LVH
- Primary endpoint
- Incident stroke
- Follow-up
- Median 3.3 years
Primary result
As reported in the abstract
Stroke
Adjusted hazard ratio (95% CI)
Prediabetes alonevs Normoglycemia without malignant LVH
1.37(0.88–2.12)
Malignant LVH alonevs Normoglycemia without malignant LVH
1.94(1.06–3.53)
Prediabetes + malignant LVHvs Normoglycemia without malignant LVH
3.07(1.66–5.70)
- Participants who developed stroke
- 116
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Stroke: prediabetes with LVH plus myocardial injury or myocardial stressPrediabetes + LVH + myocardial injuryvs Normoglycemia without malignant LVH | 3.71 (2.00–6.88) | |
| Stroke: prediabetes with LVH plus myocardial injury or myocardial stressPrediabetes + LVH + myocardial stressvs Normoglycemia without malignant LVH | 2.84 (1.44–5.58) | |
| 0.10.31310Hazard ratio (log scale) |
Alternate LVH definitions
- Results were consistent using alternate LVH definitions
Original publication
Prediabetes, Malignant Ventricular Hypertrophy and Stroke: The SPRINT Trial. Diabetes Obes Metab. Published 11 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →